幽门螺杆菌管理理念的演变
幽门螺杆菌是全球最常见的慢性细菌感染,也是胃癌最重要的危险因素。目前基于症状或高危指标的機會性检测遗漏大量无症状感染者,且常用方案根除率下降、耐药增加。随着易感性检测可及性提高,分子易感性分析有助于无创选择个体化根除方案,结合人群筛查与治疗项目可能是预防胃癌的有效策略。
要点
- 幽门螺杆菌感染多无症状,机会性检测会遗漏大量感染者。
- 常用根除方案成功率急剧下降,抗菌药物耐药增加。
- 分子易感性分析可无创指导个体化根除方案选择。
核心结论
- 改进幽门螺杆菌根除方法并结合人群筛查与治疗项目,可能是预防胃癌的有效且高效策略,尤其在承受最重负担的少数族裔和边缘化人群中。
研究设计与样本
- 原文未报告研究设计。
主要发现
- 幽门螺杆菌是全球最常见的慢性细菌感染,也是胃癌最重要的危险因素。
- 基于症状或高危指标的机会性检测遗漏大量无症状感染者,这些感染者仍面临胃癌风险。
- 慢性幽门螺杆菌感染者存在胃癌前病变风险,病变亦无症状,仅能通过内镜和活检可靠诊断。
- 常用治疗方案的成功根除率急剧下降,抗菌药物耐药增加。
- 分子易感性分析有助于无需侵入性操作即可选择个体化根除方案。
临床怎么用
- 作者认为,应放弃已被证明根除率不足的經驗性治疗。
- 作者认为,随着易感性检测可及性提高,分子易感性分析可用于选择个体化根除方案而无需侵入性操作。
- 作者认为,改进的根除方法结合人群筛查与治疗项目可能是预防胃癌的有效且高效策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Helicobacter pylori is the most common chronic bacterial infection worldwide and the most significant risk factor for gastric cancer, which remains a leading cause of cancer-related death globally. H pylori and gastric cancer continue to disproportionately impact racial and ethnic minority and immigrant groups in the United States. The approach to H pylori case-finding thus far has relied on opportunistic testing based on symptoms or high-risk indicators, such as racial or ethnic background and family history. However, this approach misses a substantial proportion of individuals infected with H pylori who remain at risk for gastric cancer because most infections remain clinically silent. Moreover, individuals with chronic H pylori infection are at risk for gastric preneoplastic lesions, which are also asymptomatic and only reliably diagnosed using endoscopy and biopsy. Thus, to make a significant impact in gastric cancer prevention, a systematic approach is needed to better identify individuals at highest risk of both H pylori infection and its complications, including gastric preneoplasia and cancer. The approach to H pylori eradication must also be optimized given sharply decreasing rates of successful eradication with commonly used therapies and increasing antimicrobial resistance. With growing acceptance that H pylori should be managed as an infectious disease and the increasing availability of susceptibility testing, we now have the momentum to abandon empirical therapies demonstrated to have inadequate eradication rates. Molecular-based susceptibility profiling facilitates selection of a personalized eradication regimen without necessitating an invasive procedure. An improved approach to H pylori eradication coupled with population-level programs for screening and treatment could be an effective and efficient strategy to prevent gastric cancer, especially in minority and potentially marginalized populations that bear the heaviest burden of H pylori infection and its complications.
引用
- Moss SF, Shah SC, Tan MC, et al. Evolving Concepts in Helicobacter pylori Management. Gastroenterology. 2023. PMID: 37806461. doi:10.1053/j.gastro.2023.09.047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。